TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02663492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sanguisorba officinalis L.
Description: Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
Study: NCT03244878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive
Description: A interactive computerized program using structured content of cognitive behavior therapy
Study: NCT04044950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR
Description: The injection will be approximately 3x10\^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
Study: NCT00996476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a
Description: One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
Study: NCT03995368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
Study: NCT01502293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
Study: NCT02673372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
Study: NCT01707342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (TMC435)
Description: Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of \[3H\]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
Study: NCT03162146

Intervention type: OTHER
Intervention: Deaths in intensive care unit
Description: Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
Study: NCT04768738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation Level Of Above Threshold
Description: Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation Level Of Subthreshold
Description: biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auricular Vagus Nerve Stimulation Sham Method
Description: Participants were shown that the device was working, but no current was given.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 5 Minutes Bicycle Exercise
Description: Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: 5 Minutes Bicycle Exercise
Description: Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 5 Minutes Bicycle Exercise
Description: Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
Study: NCT03557749

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample
Description: pea-sized amount

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample
Description: pea-sized amount

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample
Description: pea-sized amount

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: 10 ml

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: 10 ml

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoalveolar Lavage (BAL) fluid
Description: 10 ml

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastrointestinal biopsy x 2-4
Description: rectosigmoid site preferred

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: 2-4 mm punch

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: 2-4 mm punch

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin, mouth, and/or ocular swab
Description: Involved skin, mouth, and/or ocular swab for microbiota studies

Intervention type: DIAGNOSTIC_TEST
Intervention: Apheresis Product
Description: Up to 10 ml of apheresis product

Intervention type: DIAGNOSTIC_TEST
Intervention: Final cellular product
Description: A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
Study: NCT03160261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Injection
Description: Single injection of Exenatide 10μg subcutaneously
Study: NCT02480972

Intervention type: PROCEDURE
Group type: OTHER
Intervention: magnetic resonance imaging
Description: multiparametric MRI as follows:~1. diffusion weighted imaging using multiple b-values~2. Fat quantification sequence~3. perfusion MRI using ECCM agent~4. MR elastography~   ------------------------------------~5. routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)
Study: NCT06183762

Intervention type: OTHER
Intervention: No treatment is included in this protocol.
Description: No drug intervention or tissue sampling will be included in this study.

Intervention type: OTHER
Intervention: No treatment is included in this protocol.
Description: No drug intervention or tissue sampling will be included in this study.

Intervention type: OTHER
Intervention: No treatment is included in this protocol.
Description: No drug intervention or tissue sampling will be included in this study.
Study: NCT00996476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
Study: NCT06183762

Intervention type: OTHER
Intervention: No treatment is included in this protocol.
Description: No drug intervention or tissue sampling will be included in this study.
Study: NCT02234882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Study: NCT02946580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVANTIK™ (naloxegol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study: NCT04003701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control group: minimal distraction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted puncture procedure
Description: Experimental group: distraction with robot
Study: NCT01729780

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EEG-NF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG-NF
Study: NCT01933737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Micropore
Description: The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
Study: NCT01915784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuair®
Description: Inhaler with placebo only. Once daily, for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuair®
Description: Inhaler with placebo only. Once daily, for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezhaler®
Description: Inhaler with placebo only. Once daily, for 14 days.
Study: NCT00996476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
Study: NCT02529631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orlistat 60 mg
Description: In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglucosamine
Description: In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening).
Study: NCT03095690

Intervention type: OTHER
Group type: OTHER
Intervention: High resolution peripheral scanner (HRpQCT).
Description: radius and tibia osteodensitometry measurement
Study: NCT04219579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III, continuous infusion
Description: Antithrombin-III is administered continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin III, Intermittent infusion
Description: Antithrombin-III is administered intermittently
Study: NCT02579499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed high potent statin therapy
Description: Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: targeted LDL-C goal statin
Description: 1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)
Study: NCT00677326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study: NCT02749435

Intervention type: OTHER
Intervention: Use of digital disease management tool in participants with T2DM
Description: The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.

Intervention type: OTHER
Intervention: Use of digital disease management tool in participants with T2DM
Description: The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
Study: NCT05057299

Intervention type: OTHER
Intervention: retrospective data analysis
Description: chart review, analysis and reporting outcomes
Study: NCT01528176

Intervention type: DRUG
Group type: OTHER
Intervention: 10,000 IU of cholecalciferol for a total of 8 weeks
Description: Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
Study: NCT01184144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone, 30 mg, by mouth daily for 2 weeks
Study: NCT01915784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezhaler®
Description: Inhaler with placebo only. Once daily, for 14 days.
Study: NCT01617824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin 5 mg tablets for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for 4 days
Study: NCT03020251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preoperative chest physiotherapy
Description: preoperative chest physiotherapy : 5 sessions per week during 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative chest physiotherapy
Description: preoperative chest physiotherapy : 5 sessions per week during 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative rehabilitation program
Description: exercise training at home : 5 sessions per week during 3 weeks
Study: NCT01391962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: 10mg every 6 hours orally as needed for nausea,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: 10mg every 6 hours orally as needed for nausea,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: 12.5-25mg intravenous every 6 hours as needed for nausea.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: 12.5-25mg intravenous every 6 hours as needed for nausea.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Description: If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Description: If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
Study: NCT01819259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine nasal spray
Description: This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.